In 2008, Diehl et al. used BEAMing (beads, emulsion, amplification, and magnetics) to track ctDNA mutations in CRC, correlating them with tumor burden and carcinoembryonic antigen (CEA) serum levels [26]. Here, CEACAM5 is linked to neoplasm.